These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 16603301

  • 1. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease.
    Mizukami K, Tanaka Y, Asada T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep 30; 30(7):1342-6. PubMed ID: 16603301
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
    Mizukami K, Hatanaka K, Tanaka Y, Sato S, Asada T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar 17; 33(2):349-52. PubMed ID: 19166899
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
    Kanetani K, Kimura M, Endo S.
    J Nippon Med Sch; 2003 Aug 17; 70(4):313-20. PubMed ID: 12928711
    [Abstract] [Full Text] [Related]

  • 4. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
    Takahashi H, Kamata M, Yoshida K, Higuchi H, Shimizu T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb 17; 29(2):351-3. PubMed ID: 15694247
    [Abstract] [Full Text] [Related]

  • 5. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF.
    Int Clin Psychopharmacol; 1996 Sep 17; 11 Suppl 4():41-6. PubMed ID: 8923126
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression.
    Kimura M, Kanetani K, Imai R, Suzuki H, Isayama K, Endo S.
    Int Clin Psychopharmacol; 2002 May 17; 17(3):121-5. PubMed ID: 11981353
    [Abstract] [Full Text] [Related]

  • 7. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI, Fava M.
    Eur Neuropsychopharmacol; 2007 Jan 17; 17(1):32-6. PubMed ID: 16762534
    [Abstract] [Full Text] [Related]

  • 8. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients.
    Sugawara Y, Higuchi H, Yoshida K, Takahashi H, Kamata M, Naito S, Sato K, Shimizu T.
    Clin Neuropharmacol; 2006 Jan 17; 29(1):6-9. PubMed ID: 16518126
    [Abstract] [Full Text] [Related]

  • 9. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, Ueda N, Nakamura J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1034-7. PubMed ID: 17459550
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
    Morishita S, Arita S.
    Hum Psychopharmacol; 2004 Aug 30; 19(6):405-8. PubMed ID: 15303244
    [Abstract] [Full Text] [Related]

  • 11. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
    Horii A, Imai T, Kitahara T, Uno A, Morita Y, Takahashi K, Inohara H.
    J Vestib Res; 2016 Jul 02; 26(3):335-40. PubMed ID: 27392838
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
    Puech A, Montgomery SA, Prost JF, Solles A, Briley M.
    Int Clin Psychopharmacol; 1997 Mar 02; 12(2):99-108. PubMed ID: 9219045
    [Abstract] [Full Text] [Related]

  • 16. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H, Yoshida K, Higuchi H, Kamata M, Inoue K, Suzuki T, Ishigooka J.
    Neuropsychobiology; 2014 Mar 02; 70(3):173-80. PubMed ID: 25358426
    [Abstract] [Full Text] [Related]

  • 17. The dubious effect of milnacipran for the treatment of burning mouth syndrome.
    Sugimoto K.
    Clin Neuropharmacol; 2011 Mar 02; 34(4):170-3. PubMed ID: 21738026
    [Abstract] [Full Text] [Related]

  • 18. Clinical efficacy of milnacipran: placebo-controlled trials.
    Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V.
    Int Clin Psychopharmacol; 1996 Sep 02; 11 Suppl 4():29-33. PubMed ID: 8923124
    [Abstract] [Full Text] [Related]

  • 19. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
    Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.
    Clin Ther; 2008 Nov 02; 30(11):1988-2004. PubMed ID: 19108787
    [Abstract] [Full Text] [Related]

  • 20. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
    Tignol J, Pujol-Domenech J, Chartres JP, Léger JM, Plétan Y, Tonelli I, Tournoux A, Pezous N.
    Acta Psychiatr Scand; 1998 Feb 02; 97(2):157-65. PubMed ID: 9517912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.